Tolerogenic dendritic cells for treatment of acute respiratory distress syndrome

Abstract

Disclosed are compositions of matter, cells, and therapeutic protocols useful for treatment of acute respiratory distress syndrome (ARDS). In some embodiments the invention teaches treatment of ARDS caused by viruses including COVID-19 through administration of an immature population of dendritic cells at a concentration and frequency to inhibit pulmonary inflammation, alveolar leakage, and loss of pulmonary function. In some embodiments immature dendritic cells are generated by culture of autologous and/or allogeneic monocytes with IL-4 and GM-CSF without a maturation step. In other embodiments, generation of immature dendritic cells is performed by administration on NF-kappa B inhibitors. In other embodiments dendritic cells are utilized in an immature form to stimulate generation of T regulatory cells.

Dependencies are inferred from the claim text.